Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies
Recently, attention has increasingly centered on non-small-cell lung cancer (NSCLC) with immune checkpoint inhibitors application. Numerous clinical studies have underscored the potential of immunotherapy in treating resectable NSCLC, highlighting its role in improving patient outcomes. However, des...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-01-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359241312501 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841554815149146112 |
|---|---|
| author | Yuzhu Chen Fei Qi Chenhao Sun Peng Jiang Xiangyu Xue Xiaomei Yang Xiaomi Li Xin He Yishuo Wang Tongmei Zhang |
| author_facet | Yuzhu Chen Fei Qi Chenhao Sun Peng Jiang Xiangyu Xue Xiaomei Yang Xiaomi Li Xin He Yishuo Wang Tongmei Zhang |
| author_sort | Yuzhu Chen |
| collection | DOAJ |
| description | Recently, attention has increasingly centered on non-small-cell lung cancer (NSCLC) with immune checkpoint inhibitors application. Numerous clinical studies have underscored the potential of immunotherapy in treating resectable NSCLC, highlighting its role in improving patient outcomes. However, despite these promising results, there is ongoing debate regarding the efficacy of immunological combination therapy strategies, the prevalence of treatment-related side effects, the identification of predictive biomarkers, and various other challenges within the neoadjuvant context. Careful consideration is essential to maximize the benefits of immunotherapy for patients with resectable NSCLC. This article offers a detailed overview of recent advancements in neoadjuvant immunotherapy for resectable NSCLC. By examining these developments, we aim to provide new perspectives and valuable insights into the benefits and challenges of applying neoadjuvant immunotherapy in clinical settings. |
| format | Article |
| id | doaj-art-f0210f9ab2d3471ea53ede936b448d86 |
| institution | Kabale University |
| issn | 1758-8359 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj-art-f0210f9ab2d3471ea53ede936b448d862025-01-08T10:03:26ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592025-01-011710.1177/17588359241312501Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversiesYuzhu ChenFei QiChenhao SunPeng JiangXiangyu XueXiaomei YangXiaomi LiXin HeYishuo WangTongmei ZhangRecently, attention has increasingly centered on non-small-cell lung cancer (NSCLC) with immune checkpoint inhibitors application. Numerous clinical studies have underscored the potential of immunotherapy in treating resectable NSCLC, highlighting its role in improving patient outcomes. However, despite these promising results, there is ongoing debate regarding the efficacy of immunological combination therapy strategies, the prevalence of treatment-related side effects, the identification of predictive biomarkers, and various other challenges within the neoadjuvant context. Careful consideration is essential to maximize the benefits of immunotherapy for patients with resectable NSCLC. This article offers a detailed overview of recent advancements in neoadjuvant immunotherapy for resectable NSCLC. By examining these developments, we aim to provide new perspectives and valuable insights into the benefits and challenges of applying neoadjuvant immunotherapy in clinical settings.https://doi.org/10.1177/17588359241312501 |
| spellingShingle | Yuzhu Chen Fei Qi Chenhao Sun Peng Jiang Xiangyu Xue Xiaomei Yang Xiaomi Li Xin He Yishuo Wang Tongmei Zhang Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies Therapeutic Advances in Medical Oncology |
| title | Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies |
| title_full | Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies |
| title_fullStr | Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies |
| title_full_unstemmed | Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies |
| title_short | Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies |
| title_sort | navigating the landscape of neoadjuvant immunotherapy for nsclc progress and controversies |
| url | https://doi.org/10.1177/17588359241312501 |
| work_keys_str_mv | AT yuzhuchen navigatingthelandscapeofneoadjuvantimmunotherapyfornsclcprogressandcontroversies AT feiqi navigatingthelandscapeofneoadjuvantimmunotherapyfornsclcprogressandcontroversies AT chenhaosun navigatingthelandscapeofneoadjuvantimmunotherapyfornsclcprogressandcontroversies AT pengjiang navigatingthelandscapeofneoadjuvantimmunotherapyfornsclcprogressandcontroversies AT xiangyuxue navigatingthelandscapeofneoadjuvantimmunotherapyfornsclcprogressandcontroversies AT xiaomeiyang navigatingthelandscapeofneoadjuvantimmunotherapyfornsclcprogressandcontroversies AT xiaomili navigatingthelandscapeofneoadjuvantimmunotherapyfornsclcprogressandcontroversies AT xinhe navigatingthelandscapeofneoadjuvantimmunotherapyfornsclcprogressandcontroversies AT yishuowang navigatingthelandscapeofneoadjuvantimmunotherapyfornsclcprogressandcontroversies AT tongmeizhang navigatingthelandscapeofneoadjuvantimmunotherapyfornsclcprogressandcontroversies |